Dolutegravir Expanded Access Study

Summary

Dolutegravir Expanded Access Study is a clinical trial^[1].

Key Facts

• Dolutegravir Expanded Access Study is in the country of Austria^[2].
• Dolutegravir Expanded Access Study is in the country of Belgium^[3].
• Dolutegravir Expanded Access Study is in the country of Brazil^[4].
• Dolutegravir Expanded Access Study is in the country of Canada^[5].
• Dolutegravir Expanded Access Study is in the country of France^[6].
• Dolutegravir Expanded Access Study is in the country of Germany^[7].
• Dolutegravir Expanded Access Study's instance of is recorded as clinical trial^[8].
• Dolutegravir Expanded Access Study's start time is recorded as +2012-06-30T00:00:00Z^[9].
• Dolutegravir Expanded Access Study's end time is recorded as +2018-08-31T00:00:00Z^[10].
• Dolutegravir Expanded Access Study's number of participants is recorded as {'unit': '1', 'amount': '+200'}^[11].
• Dolutegravir Expanded Access Study's title is recorded as A Dolutegravir Open Label Protocol for HIV Infected, Adult and Adolescent Patients With Integrase Resistance^[12].
• Dolutegravir Expanded Access Study's short name is recorded as DEAP^[13].
• Dolutegravir Expanded Access Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+12'}^[14].
• Dolutegravir Expanded Access Study's ClinicalTrials.gov ID is recorded as NCT01536873^[15].
• Dolutegravir Expanded Access Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+99'}^[16].
• Dolutegravir Expanded Access Study's research intervention is recorded as dolutegravir^[17].
• Dolutegravir Expanded Access Study's clinical trial phase is recorded as phase III clinical trial^[18].
• Dolutegravir Expanded Access Study's research site is recorded as GSK^[19].
• Dolutegravir Expanded Access Study's research subject recruitment status is recorded as Coronavirus^[20].
• Dolutegravir Expanded Access Study's study type is recorded as interventional study^[21].